Changes In Uric Acid Levels Research Articles

Effects of Acute and One-Week Supplementation with Montmorency Tart Cherry Powder on Food-Induced Uremic Response and Markers of Health: A Proof-of-Concept Study

Metabolic conditions, such as gout, can result from elevated uric acid (UA) levels. Consuming high-purine meals increases UA levels. Therefore, people with hyperuricemia typically must avoid ingesting such foods. Polyphenols have been shown to reduce uric acid levels and tart cherries (TCs) are a rich source of phenolic and anthocyanin compounds. This proof-of-concept study evaluated whether ingesting TCs with a purine-rich meal affects the uricemic response. Methods: A total of 25 adults (15 males and 10 females, 85.0 ± 17 kg, 40.6 ± 9 years, 29.1 ± 4.9 kg/m2) with elevated fasting UA levels (5.8 ± 1.3 mg/dL) donated a fasting blood sample. In a randomized, double-blind, crossover, placebo-controlled, counterbalanced manner, participants ingested capsules containing 960 mg of a placebo (PLA) or concentrated TC powder containing 20.7 mg of proanthocyanins with a serving of hot soup (10 g of carbohydrate, 2 g protein, and 1 g fat) containing 3 g of purines (1 g of adenosine 5′-monophosphate, 1 g of disodium 5′-guanylate, and 1 g of disodium 5′-inosinate). Blood samples were obtained at 0, 60, 120, 180, and 240 min after ingestion to assess changes in uric acid levels and pharmacokinetic profiles. Cell blood counts, a comprehensive metabolic panel, cytokines, inflammatory markers, and subjective side effects ratings were analyzed on baseline (0 min) and post-treatment (240 min) samples. Participants continued consuming two capsules/day of the assigned treatment for one week and then repeated the experiment. Participants observed a 14-day washout and then repeated the experiment while ingesting the alternate treatment. Data were analyzed using general linear model (GLM) statistics with repeated measures, pairwise comparisons, and percentage change from baseline with 95% confidence intervals (CIs). Results: No statistically significant interaction effects or differences between treatments were seen in uric acid levels or PK profiles. Analysis of percent changes from baseline revealed that TC ingestion reduced the blood glucose levels following the ingestion of the high-purine meal (−4.2% [−7.7, −0.7], p = 0017). Additionally, there was some evidence that TC ingestion attenuated the increase from baseline in IL-1β and IL-10 and increased INF-γ. No significant differences were seen in the remaining health markers or subjective side effects ratings. Conclusions: Acute and one-week TC supplementation did not affect the uricemic response to ingesting a high-purine meal in individuals with mildly elevated UA levels. However, there was some evidence that TC supplementation may blunt the glycemic response to ingesting a meal and influence some inflammatory cytokines. Registered clinical trial NCT04837274.

A high-performance wearable microneedle sensor based on a carboxylated carbon nanotube-carbon nanotube composite electrode for the simultaneous detection of uric acid and dopamine

Uric acid (UA) and dopamine (DA) are crucial biomarkers in the human body. However, there is limited research on detecting UA or DA in subcutaneous interstitial fluid (SISF), and no studies on their simultaneous detection in SISF. Here, we developed an electrochemical microneedle sensor based on the carboxylated carbon nanotubes/multiwalled carbon nanotubes (CCNT/CNT) composite electrode for the simultaneous detection of UA and DA. Highly carboxylated CCNT was prepared and mixed with CNT and organosilicon-modified acrylic resin to form the CCNT/CNT composite. The carboxyl functional groups of CCNT enhance the electrode’s adsorption of UA and DA, while CNT improves electron conduction. The sensor achieves a wide linear detection range for UA (5–600 μM) with high sensitivity (7.13 μA μM−1 cm−2) and linearity (R2 = 0.994), as well as a wide linear range for DA (2–200 μM) with high sensitivity (13.31 μA μM−1 cm−2) and linearity (R2 = 0.994). The sensor achieved simultaneous detection of DA and UA in artificial interstitial fluid (ISF), with sensitivity and linearity remaining nearly unchanged compared to that in PBS, and is not affected by high levels of ascorbic acid (AA). Finally, the sensor successfully detected changes in UA levels in ISF of subjects before and after alcohol consumption in vivo, demonstrating its practical application capabilities. This study presents a practical strategy for detecting human biomarkers characterized by low cost, easy fabrication and excellent performance of electrode materials, and a well-designed microneedle sensor preparation scheme, making it highly promising for further research extension.

Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients.

Pyrazinamide is one of the antitubercular drugs used for 2 months in the intensive phase. One of the adverse effects of pyrazinamide is hyperuricemia, with a symptom of arthralgia. This study aims to analyze the incidence of hyperuricemia and arthralgia and their causality in pulmonary tuberculosis (TB) patients undergoing treatment in the intensive phase. It was an analytic observational study with a prospective cohort design. Three ml of blood from each pulmonary TB patient was withdrawn to examine uric acid levels before and after 2 months of treatment with pyrazinamide. The Wilcoxon test was used to analyze changes in uric acid levels and the Chi-square test to analyze the association between uric acid levels and arthralgia. Naranjo algorithm is used to analyze the causality of hyperuricemia. Twenty pulmonary TB patients met the inclusion criteria in this study. Eight out of 12 (60%) TB patients showed uric acid levels ≥7 mg/dl and 8 of them (66.6%) showed symptoms of arthralgia. The median uric acid level increased significantly before (5.14 mg/dl) and after 2 months of treatment (7.74 mg/dl), P-value = 0.001. Uric acid levels ≥7 mg/dl were significantly associated with arthralgia (P-value = 0.017; odds ratio 14.00; 95% confidence interval 1.25-156.61). Based on the Naranjo algorithm, those with hyperuricemia, eight and four patients had a total score of 7 and 8, respectively, which are classified as probable. Uric acid levels significantly increased during the intensive phase. Pulmonary TB patients with hyperuricemia are a risk factor for arthralgia.

Risk factors for bloodstream infection among patients admitted to an intensive care unit of a tertiary hospital of Shanghai, China

Blood flow infections (BSIs) is common occurrences in intensive care units (ICUs) and are associated with poor prognosis. The study aims to identify risk factors and assess mortality among BSI patients admitted to the ICU at Shanghai Ruijin hospital north from January 2022 to June 2023. Additionally, it seeks to present the latest microbiological isolates and their antimicrobial susceptibility. Independent risk factors for BSI and mortality were determined using the multivariable logistic regression model. The study found that the latest incidence rate of BSI was 10.11%, the mortality rate was 35.21% and the mean age of patients with BSI was 74 years old. Klebsiella pneumoniae was the predominant bacterial isolate. Logistic multiple regression revealed that tracheotomy, tigecycline, gastrointestinal bleeding, shock, length of hospital stay, age and laboratory indicators (such as procalcitonine and hemoglobin) were independent risk factors for BSI. Given the elevated risk associated with use of tracheotomy and tigecycline, it underscores the importance of the importance of cautious application of tracheostomy and empirical antibiotic management strategies. Meanwhile, the independent risk factors of mortality included cardiovascular disease, length of hospital stay, mean platelet volume (MPV), uric acid levels and ventilator. BSI patients exhibited a significant decrease in platelet count, and MPV emerged as an independent factor of mortality among them. Therefore, continuous monitoring of platelet-related parameters may aid in promptly identifying high-risk patients and assessing prognosis. Moreover, monitoring changes in uric acid levels may serve as an additional tool for prognostic evaluation in BSI patients.

Relieving urinary tract obstructions may increase the risk of gouty arthritis in patients with hyperuricemia and postrenal obstructions.

To evaluate the effect of relieving urinary tract obstructions (RUO) on the risk of gouty arthritis in patients with postrenal obstructions and hyperuricemia. We retrospectively analyzed the clinical data of 130 patients with urinary tract obstructions at Rongcheng People's Hospital from 2018 to 2021. Patients were divided into groups A (n = 62) and B (n = 68) according to the treatment method. Patients in group A underwent conservative treatments, such as drugs, extracorporeal shock wave lithotripsy (ESWL), and hemodialysis. Patients in Group B underwent catheterization, cystostomy, nephrostomy, or double J ureteral catheterization for rapid RUO. The ages of groups A and B were 58.40 ± 17.69 and 59.63 ± 16.12 years, respectively (P = .42). Before treatment, the serum uric acid values were 572.05 ± 106.93 and 567.79 ± 97.21 µmol/L, respectively (P = .94); serum creatinine values were 226.66 ± 269.67 and 280.15 ± 200.75 µmol/L, respectively (P = .88); and urine volumes were 913.23 ± 481.92 and 886.18 ± 552.72 mL/24 h, respectively (P = .08). No significant differences in the general data were identified between the two groups (P > .05). The effects of the two treatments on the incidence of gout in patients with hyperuricemia complicated by postrenal obstruction were compared based on changes in uric acid level, creatinine level, and urine volume within 1 week after treatment. Multivariate logistic regression analysis was used to analyze clinical factors that increased the incidence of gout after RUO. The gout incidence rates in group A before and after treatment were 8.1% (5/62) and 6.5% (4/62), respectively (P > .99). The gout incidence rates in group B before and after treatment were 4.4% (3/68) and 19.1% (10/68), respectively (P = .01). Group B had a statistically significant increase in the gout incidence rate after RUO (P < .05). Multivariate logistic regression analysis showed that having an age > 60 years, urine volume ≤400 mL/24 h, and creatinine level > 186 µmol/L before treatment were risk factors for gout in patients with hyperuricemia after RUO. Relieving urinary tract obstruction increases the risk of gouty arthritis in patients with hyperuricemia and acute postrenal obstruction. Age, urine volume, and creatinine levels before treatment are risk factors for gout in patients with hyperuricemia after RUO.

Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.

Few studies reported the effects of growth hormone-secreting pituitary adenoma (GHPA) on uric acid (UA) metabolism and the relationship between growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels and UA are controversial. This study aimed to evaluate the relationship between IGF-1 and UA in patients with GHPA and to further clarify whether UA levels are associated with GHPA disease activity by follow-up. A longitudinal study of 424 GHPA patients presenting to Beijing Tiantan Hospital, Capital Medical University between January 2015 and January 2023 was conducted. Spearman's correlation tests were performed to examine the relationship between IGF-1 and UA at baseline. Univariate and multivariate linear regression analysis was conducted to investigate the independent association between UA and IGF-1. Changes in postoperative IGF-1 and UA levels were followed prospectively, and the differences in UA levels between the biochemical remission and nonremission groups were compared. At baseline, male patients, the lower the age, the higher the IGF-1 and body mass index (BMI), and the higher the UA levels. IGF-1 was significantly associated with UA after controlling for sex, age, and BMI (r = 0.122, P = 0.012). In adjusted multiple linear regression analysis, IGF-1 was independently associated with UA, and UA levels increased significantly with increasing IGF-1. During postoperative follow-up, UA decreased gradually as IGF-1 levels decreased. At 12 months postoperatively, UA levels were significantly lower in the biochemical remission group than in the nonremission group (P = 0.038). In patients with GHPA, UA levels are associated with disease activity. Changes in UA levels should be taken into account in the comprehensive treatment of GHPA, patients presenting with HUA should be given lifestyle guidance and appropriate urate-lowering treatment according to their condition to better improve their prognosis.

Associations of circulating multiple metals with the risk of incident hyperuricemia and the average annual change in uric acid levels

BackgroundHyperuricemia has been linked to exposure to certain metals in cross-sectional studies. However, prospective studies evaluating the associations of multiple metal exposures with incident hyperuricemia are scarce. ObjectivesTo prospectively investigate the associations of multiple metal/metalloid concentrations with incident hyperuricemia as well as average annual change in uric acid levels in a longitudinal cohort. MethodsA longitudinal cohort study included 3957 subjects who were free of cardiovascular disease with certain risk factors for cardiovascular disease at baseline. Incident hyperuricemia was ascertained if serum uric acid level was ≥ 420 μmol/L for men and ≥ 360 μmol/L for women during the follow-up visit in 2013. The relationships between 17 single plasma metals/metalloids and incident hyperuricemia were assessed using unconditional logistic regression models. For metals/metalloids significantly related to incident hyperuricemia, we further utilized generalized linear regression models to evaluate their associations with the average annual change in uric acid levels. Finally, we applied the weighted quantile sum (WQS) regression to investigate the joint effects of metals/metalloids on hyperuricemia risk and uric acid changes, and to identify the most significant metals. ResultsAfter adjusting for potential confounders, plasma aluminum, arsenic, barium, lead, strontium, vanadium, and zinc concentrations were positively associated with incident hyperuricemia in both main analyses and sensitivity analyzes. Compared to the lowest quartiles, participants in the highest quartiles had 63 %−125 % higher risks of incident hyperuricemia (all FDR < 0.05). Furthermore, the positive associations of these seven metals with an average annual uric acid increase reinforced the findings. Finally, the WQS analyses showed that plasma metals mixtures were positively associated with the risk of incident hyperuricemia (OR: 1.47; 95 % CI: 1.23, 1.76) and the average annual change in uric acid levels (β: 3.17; 95 % CI: 2.42, 3.93), and strontium and vanadium were the most heavily weighted metals, respectively. ConclusionOur findings identify aluminum, arsenic, barium, lead, strontium, vanadium, and zinc exposures as independent risk factors for hyperuricemia and provide new insights into the prevention of hyperuricemia.

Association of Uric Acid in Oral Health, Periodontal Disease, and Systemic Disorders: A Systematic Review

Background: The relationship between periodontitis or periodontal disease (PD) with uric acid (UA) is controversial. Furthermore, a rise in UA levels in common systemic disorders documented to be liked to PD must be understood. Objectives: The objective is to determine the association of UA levels with periodontal health and disease states by a systematic review of evidence from observational studies. Furthermore, we aimed to group secondary research papers which showed systemic diseases linked to periodontitis (SDLP) for the changes in UA levels in serum and discuss the consequences. Materials and Methods: A systematic review was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. The literature search was followed by qualitative assessment using the Newcastle–Ottawa scale when evaluating PD with UA associations. A similar strategic search system was used for identifying secondary studies (systematic reviews with meta-analyses or [SRMA]) for identifying UA levels in common SDLP. Results: Out of 212 selected studies, 40 underwent full-text analysis; 6 were eligible for systematic review. The current review summarizes that overall PD cases have significantly more UA levels than healthy individuals or controls from data from three observational studies. In the case of SDLP, around 8 SRMA (conducted on = 164 observational studies) revealed a significant association (P &lt; 0.05 in all instances) with serum hyperuricemia; cancer incidence and progression were more in women with raised UA than in men. Conclusion: The review showed that UA levels were significantly altered in PD compared to healthy individuals. However, the available evidence is inadequate to establish whether UA is diminished or elevated in periodontal disease. The SDLP all showed a significant association with raised serum UA levels with cancers affecting more women than men with high UA levels.

Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.

Xanthine oxidase (XO) inhibitors may slow down chronic kidney disease (CKD) progression. The comparative effectiveness of the different urate-lowering drugs is unknown. The aim of this study was to determine whether urate-lowering therapy with an XO inhibitor (febuxostat) and that with a uricosuric drug (benzbromarone) are comparable in slowing renal function decline in patients with CKD complicated with hypertension and hyperuricemia. This study was an open-label randomized parallel-group clinical trial of 95 patients with stage G3 CKD in Japan. The patients had hypertension and hyperuricemia without a history of gout. They were randomized to receive febuxostat ( n = 47; febuxostat group) or benzbromarone ( n = 48; benzbromarone group) and titrated to reduce their serum urate level to <6.0 mg/dl. The primary end-point was change in estimated glomerular filtration rate (eGFR) from baseline to 52 weeks. The secondary end-points included changes in uric acid level, blood pressure, urinary albumin-to-creatinine ratio, and XO activity. Of the 95 patients, 88 (92.6%) completed the trial. There were no significant differences in change in eGFR (in ml/min/1.73 m 2 ) between the febuxostat [-0.23, 95% confidence interval (CI), -2.00 to 1.55] and benzbromarone (-2.18, 95% CI, -3.84 to -0.52) groups (difference, 1.95; 95% CI, -0.48 to 4.38; P = 0.115) nor in the secondary end-points, except for XO activity. Febuxostat significantly reduced XO activity ( P = 0.010). There were no significant differences in primary and secondary outcomes between the groups. A decrease in eGFR was significantly less in the febuxostat group than that of the benzbromarone group in the CKDG3a, but not in CKDG3b, in the subgroup analysis. There were no adverse effects specific to either drug. No significant differences were found in the effects of febuxostat and benzbromarone in renal function decline in stage G3 CKD complicated with hyperuricemia and hypertension.

The Amount of Food Ingested and Its Impact on the Level of Uric Acid in the Blood Plasma of Snakes.

In mammals, lipemic blood from sampling too soon after an animal feeds can have substantial effects on biochemical values. Plasma biochemical values in reptiles may be affected by species, age, season, and nutritional state. However, fasting status is not routinely considered when sampling reptile blood. Assessing uric acid levels in snakes is an important part of the diagnosis of the renal disease. However, the use of this biochemical indicator is undervalued without knowledge of natural uric acid fluctuations and the lack of differentiation from pathological changes. This study aimed to look at the relationship between snake feeding and uric acid concentrations. The investigation aims to better understand the feed-induced changes that occur and render the analysis of this biochemical parameter a more potent diagnostic tool. The study used ten snakes belonging to seven species, and basal uric acid values were evaluated by blood biochemical analysis before feeding. The snakes were fed in two rounds, with successive blood sampling and monitoring of uric acid changes carried out for each. The snakes were fed approximately 50% more with the second round of feeding to investigate the relationship between food supply and uric acid level. The findings show feeding led to substantial elevations in uric acid values, whereby postprandial concentrations were significantly elevated for up to 8 days after feeding. The findings show the significant changes in uric acid levels that occur after feeding and the similarities between postprandial rises in uric acid and those reported in snakes with renal disease. To minimize misdiagnosis and differentiate transient postprandial hyperuricemia from pathological increases, it is recommended that sufficient anamnestic data on time since the last feeding be collected, as well as repeated samples following weeks of fasting. This knowledge is crucial because the amount of feed in terms of intensity and volume has a significant effect on uric acid levels in the blood of snakes.

Association between liver-type fatty acid-binding protein and hyperuricemia before and after laparoscopic sleeve gastrectomy.

BackgroundLiver-type fatty acid-binding protein (FABP1) contributes to metabolic disorders. However, the relationship between FABP1 and hyperuricemia remains unknown. We aimed to evaluate the correlation between serum FABP1 and hyperuricemia in patients with obesity before and after laparoscopic sleeve gastrectomy (LSG).MethodsWe enrolled 105 patients (47 men and 58 women) with obesity who underwent LSG. They were divided into two groups: normal levels of uric acid (UA) (NUA, n = 44) and high levels of UA (HUA, n = 61) with matching sexes. FABP1 levels and other biochemical parameters were measured at baseline and 3, 6, and 12 months after LSG.ResultsSerum FABP1 levels were significantly higher in the HUA group than in the NUA group (34.76 ± 22.69 ng/mL vs. 25.21 ± 21.68 ng/mL, P=0.024). FABP1 was positively correlated with UA (r=0.390, P=0.002) in the HUA group. The correlation still existed after adjusting for confounding factors. Preoperative FABP1 levels were risk factors for hyperuricemia at baseline. UA and FABP1 levels decreased at 3, 6, and 12 months postoperatively. FABP1 showed a more significant decrease in the HUA group than in the NUA group at 12 months (27.06 ± 10.98 ng/mL vs. 9.54 ± 6.52 ng/mL, P=0.003). Additionally, the change in FABP1 levels positively correlated with changes in UA levels in the HUA group 12 months postoperatively (r=0.512, P=0.011).ConclusionsFABP1 was positively associated with UA and may be a risk factor for hyperuricemia in obesity. FABP1 levels were higher but decreased more after LSG in obese patients with hyperuricemia than in those without hyperuricemia.

The Effectiveness of Ergonomic Gymnastics Against Changes in Uric Acid Levels

Background: Uric acid is the end product of purine metabolism, where purines are one of the components of nucleic acids found in the nucleus of body cells. Gout attacks the joints of the body and generally attacks the joints of the fingers, heels, toes, elbows, knees, and wrists. One of the treatments for high uric acid levels in the body is ergonomic exercise.&#x0D; Objectives: The purpose of this study was to analyze the effectiveness of ergonomic exercise on changes in uric acid levels in the community.&#x0D; Methods: The type of research used is Pre-Experimental with One Group Pre-Post Test Design. Sampling using the Non Probability Sampling method with the Consecutive Sampling technique with a sample of 30 respondents. This study provides an intervention for patients with gout arthritis in the form of ergonomic exercise. The implementation of the intervention begins with a Pre-Test (measurement of uric acid levels), then giving an ergonomic exercise intervention for 4 weeks (1x a week with a duration of 30 minutes), then a Post-Test (measurement of uric acid levels) is carried out. The instrument used is a multi-check uric acid measuring instrument, SOP for the implementation of ergonomic exercises, and implementation observation sheets.&#x0D; Results: The results of the study were that the majority of the majority age was in the late adult category (36-45 years), the majority sex was in the female sex category of 19 respondents (63.3%), and uric acid levels before being given ergonomic exercise intervention were the majority in the high category. by 28 respondents (93.3%). while the uric acid levels after the ergonomic exercise intervention were mostly in the normal category of 25 respondents (83.3%). The results of the Wilcoxon test analysis were obtained (p = 0.000 = 0.05) where ergonomic exercise was effective in reducing uric acid levels.&#x0D; Conclusion: The results of this study indicate that there is a significant effect of ergonomic exercise on reducing people's uric acid levels, so the researchers recommend to the community, especially gout arthritis sufferers, to make ergonomic exercise interventions one of the intervention options that can be done independently, practically and efficiently in reducing levels. gout and the need for attention to the regulation of a healthy lifestyle to prevent more severe complications in the future.

EFFECT OF LIME JUICE (CITRUS AURANTIFOLIA) ON BLOOD URIC ACID LEVELS IN ELDERLY

Health problems commonly experienced by the elderly are quite complex along with the changes they experience biologically or psychosocially. Some of the health problems that commonly occur include arthritis or joint inflammation, which is a disease that attacks the joints. This inflammation can occur due to many factors, one of which is uric acid levels. The elderly are one of the groups that are susceptible to diseases including arthritis (Gout). Gout is a disease that arises due to excessive blood uric acid levels. When uric acid levels are high in the blood, it is called hyperuricemia. The cause of excessive blood uric acid levels is the production of uric acid in the body more than its disposal. Uric acid in the blood can be excreted through urine. The purpose of this study was to determine changes in uric acid levels before and after treatment of lime juice (Citrus aurantifolia).This research method is an experimental research research design Pre and Post Test Group Design without control. The study was conducted at the 'Aisyiyah Elderly Homes, Surakarta in July 2021.The results showed that the distribution was mostly in elderly women, namely 20 people. There is a significant difference in uric acid levels before and after treatment of lime juice (Citrus aurantifolia) which is indicated by the p value = 0.000, where the p value &lt;0.05.The conclusion of this study is the effect of giving lime juice (Citrus aurantifolia) to changes in blood uric acid levels.

Serum uric acid as biomarker for mania: An exploratory prospective study

Bipolar Disorder is a major mental illness characterized by episodic occurrence of mood symptoms which can be of mania, depression or a mixed episode. The role of Uric Acid in the etiopathogenesis of episodic mental illnesses might be considered recognized long back in 19th century. Lithium was used as treatment for gouty arthritis and that in some cases helped to control mental illnesses. Multiple role of uric acid in the Central Nervous System have been recognized now. In the present study 30 patients in manic episodes were included and their serum Uric Acid level was compared to age and sex matched healthy controls twice at the interval of three weeks. It was found that Uric Acid level of cases was significantly higher than in controls before the initiation of treatment. Uric Acid level of manic group showed a significant decline after three weeks of treatment initiation. There was no significant change in Uric Acid level of control group after three weeks Serum Uric Acid levels are elevated during manic phase of Bipolar Disorder and decreases after initiation of treatment. There may be more research to find whether uric acid can be considered a biomarker for Bipolar illnesses and also an indicator for treatment response.

Estimation of Serum, Salivary, and Gingival Crevicular Uric Acid of Individuals With and Without Periodontal Disease: A Systematic Review and Meta-analysis.

ABSTRACTIntroduction:Uric acid (UA) levels in serum, salivary, and gingival crevicular fluid (GCF) may be associated with periodontal diseases. Hence, this study aimed to estimate the UA concentration in serum, saliva, and GCF of periodontal disease and non-periodontal disease subjects by conducting a systematic review and a meta-analysis of the reported studies.Materials and Methods:A review of the available literature was searched in the electronic databases of PubMed, Cochrane, Science Direct, and EBSCO for the relevant publications. All the related case–control, cross-sectional, and cohort studies reporting the UA levels in the blood, salivary, and GCF between periodontal disease patients and healthy controls were analyzed. Significant heterogeneity was observed in the studies. Hence, a continuous random-effects model was used. The findings are described in forest plots with the point estimations and 95% confidence interval (CI). A value of P less than 5% was considered as a significant heterogeneity test.Results:Of the initial 166 study titles screened, 14 reported papers were eligible for quantitative review. The subgroup analysis of serum UA revealed a mean difference of 0.299 (95% CI: 0.029–0.569, I2=85.64%, P<0.001), indicating an increase in the UA levels in periodontal disease. However, the subgroup analysis by salivary UA demonstrated a mean difference of −0.783 (95% CI: −1.577–0.011, I2= 94.62%, P<0.001), suggesting a lower side of the UA level in periodontal diseases. The subgroup analysis based on case–control studies showed a mean difference of 0.004 (95% CI: −0.286–0.294, I2=84.99%, P<0.001), indicating no changes in UA levels in periodontal disease. On the contrary, cohort studies and cross-sectional studies showed a mean difference : 95% CI: −1.016, −3.272–1.241, I2=97.84%, P<0.001 and 95%: −1.230, −4.410–1.949, I2=97.7%, P<0.001, indicating reduction in UA levels in periodontal disease cases.Conclusion:The current review suggests an increase in the serum UA levels in periodontal disease than in healthy controls. Contrarily, the salivary UA levels decreased in periodontal disease patients. It is unknown why UA levels are opposite in the blood and saliva of periodontal disease patients requiring further explanation.

Anti-hyperurisemic Activity of Combination of Beetroot Powder (Beta vulgaris L.) And Allopurinol in Potassium Oxonate-Induced White Rats

Introduction: Hyperuricemia is an abnormally high quantity of uric acid in the blood. Allopurinol is a type of xanthine oxidase inhibitor commonly used to lower uric acid levels in the general population. However, large doses of allopurinol can produce harmful effects, one of which being hepatotoxicity. The antioxidant activity of beetroot powder is high, and it has an antihyperuricemic effect. Giving beetroot powder and allopurinol together is intended to minimize allopurinol's adverse effects and give a positive increase in lowering uric acid levels. This study aims to evaluate the anti hyperuricemia effect of beetroot powder (Beta vulgaris L.) and allopurinol combination in white rats (Rattus novergicus strain Sprague Dawley) induced by potassium oxonate.Methods: This an experimental study with a randomized pre and post-test control group design. In this experiment, twenty rats were placed into four treatment groups; KP = Positive Control (hyperuricemic rats) + standard feed and drink; G1 = hyperuricemic rats + allopurinol 1,8 mg/Kg BW/day); G2 = Hyperuricemic rats + beet powder 1.56 g/Kg BW/day; G3 = hyperuricemic rats + allopurinol 1,8 mg/Kg BW/day and beetroot powder 1,56 g/Kg BW/day. On day 0 and day 28, the amounts of uric acid were measured. Data obtained were analyzed using SPSS version 23 for windows.Results: The mean pre-post changes in uric acid levels in each group were KP = 8.97 ± 0.48 mg/dl, G1 = 2.06 ± 0.15 mg/dl, G2 = 2.24 ± 0.10 mg/dl, and G3 = 2.11 ± 0.86 mg/dl. The mean pre-post changes in MDA levels in each group were KP = 8.14 ± 0.39 nmol/mL, G1 = 2.01 ± 0.38 nmol/mL, G2 = 3.13 ± 0.30 nmol/mL, and G3 = 2.35 ± 0.19 nmol/mL.Conclusion: Beetroot powder and allopurinol combination given for 28 days significantly reduced uric acid and MDA levels in potassium oxonate-induced white rats.

Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study

IntroductionMeasurement of blood Favipiravir (FPV) levels and accumulation of data in COVID-19 patients are critical for assessing FPV efficacy and safety. We performed a retrospective study based on measurements of blood levels of FPV and related factors in COVID-19 patients admitted to our hospital. Furthermore, we also investigated the association between blood FPV levels and uric acid level alterations before and after FPV administration. MethodsWe enrolled 27 COVID-19 patients who had received FPV treatment at Hokushin General Hospital from April 1 to December 31, 2020. Age, gender, COVID-19 severity, presence of comorbidities, and laboratory data for each subject were investigated to identify factors that correlate with blood FPV levels. Uric acid levels were measured before and after FPV administration and a difference between the levels (i.e., a change of uric acid level) was evaluated. ResultsWhen a significant univariate variable was input by the stepwise method and a combination of variables that maintained statistical superiority was searched, serum ferritin was the only factor that independently affected blood FPV level. Furthermore, in the high-FPV group (20 μg/mL or more), a significant increase in uric acid levels was observed after FPV administration. The increment value was significantly larger than that in the low-FPV group (less than 20 μg/mL). ConclusionsFerritin level was an important independent factor inversely affecting blood FPV level. Furthermore, a high blood FPV level induced the elevation of uric acid levels in COVID-19 treatment.

Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China.

BackgroundThe prevalence of hyperuricemia (HUA) and gout continues to increase in China. Research suggests that HUA may be related to many diseases other than gout. However, further population research is required to investigate the association between HUA and metabolic syndromes. This study sought to investigate the prevalence of HUA in an average population in China, and the association between serum uric acid (UA) levels and related metabolic disorders.MethodsThis multicenter retrospective real-world study examined the hospital information system data of 4 tertiary hospitals in 3 provinces in China. The data of patients aged between 18 and 80 years, who had attended at least 1 medical appointment at which their UA level was recorded, were analyzed to evaluate associations between UA levels and metabolic disorders.ResultsAmong the 374,506 enrolled subjects (49.7% male; mean age 51.5 years old), the overall prevalence of HUA and gout were 14.8% and 0.5%, respectively. The prevalence was higher among males than females (17.6% vs. 12.0%, 0.8% vs. 0.1%; both P<0.001). Groups exhibiting higher UA levels had increased adjusted odds ratios for dyslipidemia and chronic kidney disease (CKD) in both sexes. Changes in UA levels from the baseline were negatively correlated with changes in the estimated glomerular filtration rate and hemoglobin A1c among both sexes (all P<0.001), and were positively correlated with changes in total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) (all P<0.05) among males, and changes in TC, TG, LDL-C and glucose (all P<0.001) among females.ConclusionsHUA is associated with dyslipidemia and CKD both cross-sectionally and longitudinally. Similar phenomena were observed in both sexes.

PERBANDINGAN EFIKASI DAN KEAMANAN PENGGUNAAN FEBUXOSTAT DAN ALLOPURINOL PADA PASIEN GOUT

Febuxostat and allopurinol are xanthine oxidase inhibitors to reduce uric acid levels. The research aimed to determine the differences in efficacy and safety of using febuxostat and allopurinol for gout patients. This research was conducted using a narrative review method for articles obtained from the PubMed and Willey databases published in 2010-2021. From the article exploration, 5 articles were reviewed showing that the determination of drug efficacy was seen by monitoring the changes in uric acid levels for 6 months from the beginning of drug use. Febuxostat and allopurinol had good efficacy in achieving target uric acid levels &lt; 6 mg/dL, however, febuxostat was superior to allopurinol in usual doses. Febuxostat 80 mg had superior efficacy to febuxostat 40 mg, while febuxostat 40 mg had superior efficacy to allopurinol 300 mg (p &lt; 0.05). For safety, febuxostat and allopurinol possessed similar side effects in the form of upper respiratory tract infection, diarrhea, headache, nausea and vomiting.

Association between hyperuricemia and incidence risk for cardiometabolic abnormity in children

Objective: To investigate the relationships between hyperuricemia and the incidence risk for cardiometabolic abnormity in children. Methods: Data were obtained from School-based Cardiovascular and Bone Health Promotion Program. In 2017, a total of 15 391 children aged 6-16 years in Beijing were selected through stratified cluster sampling at baseline survey. Follow-up investigation was conducted in 2019. Logistic regression model was used to analyze the relationships of uric acid quartiles and change in uric acid levels with incidence risks for cardiometabolic abnormity (hypertension, hyperglycemia and dyslipidemia). Results: A total of 8 807 children (4 376 boys, 4 431 girls) were included in the analysis, the average age of the children was (11.1±3.3) years at baseline survey. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of incidence risk for hypertension in the third and fourth quartiles of the UA were 1.39 (1.11-1.75) and 1.56 (1.19-1.81), respectively. The ORs and 95% CIs of risk for high LDL-C in the second, third and fourth quartiles were 1.88 (1.16-3.05),1.98 (1.23-3.17) and 2.25 (1.42-3.57). The uric acid level increased by one standard deviation, the risk increased by 17% for hypertension and 27% for high LDL-C. The uric acid level increased by 10 μmol/L, the risk increased by 2.1% for hypertension and 2.9% for high LDL-C. The gender-stratified analysis showed that the similar results. The ORs and 95% CIs were 1.32 (1.09-1.60) and 1.50 (1.05-2.16) for hypertension, 1.90 (1.38-2.60) and 2.96 (1.58-5.52) for high TC, 1.78 (1.26-2.51) and 2.84 (1.60-5.03) for high LDL-C in the groups of newly diagnosed hyperuricemia and persistent hyperuricemia. Conclusions: Higher uric acid level was associated with increased incidence risks for hypertension, abnormal TC and LDL-C. Maintaining optimal uric acid level by children might contribute to the early prevention of cardiovascular diseases.